logo

For the Inventor, By the Inventor

Morganville, NJ, United States of America

Dinanath F Rane

This inventor holds 26 USPTO granted patents, plus 1 CIPO patent, primarily in Cancer Treatment. Top assignees: Schering Corporation, Pharmacopeia Inc.. Active years: 1980-2009.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dinanath F Rane. Retrieved from https://idiyas.com/inventor/dinanath-f-rane

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26

% Patents Active = 84.6


Average Co-Inventor Count = 3.7

ph-index = 11

Forward Citations = 330(Granted Patents)


Location History:

  • Verona, NJ (US) (1981)
  • Emerson, NJ (US) (1980 - 1984)
  • Sayreville, NJ (US) (1987 - 1988)
  • Morganville, NJ (US) (1991 - 2009)

Company Filing History:

goldMedal26 out of 1,829 
 
Schering Corporation
 patents
silverMedal2 out of 101 
 
Pharmacopeia Inc.
 patents
where one patent can have more than one assignee

Years Active: 1980-2009

Loading Chart...
Loading Chart...
Areas of Expertise:
Farnesyl Protein Transferase
Cancer Treatment
Tricyclic Compounds
G-Protein Function
Antitumor Agents
Proliferative Diseases
Anti-Fungal Agents
Pharmaceutical Compositions
Microbiological Methylation
Aminoglycosyl-Aminoglycosides
2-Azolylmethyl Compounds
Dihydrobenzo(B)Thiophenes
26 patents (USPTO):Explore Patents
1. 7585864 - Farnesyl protein transferase inhibitors and their use to treat cancer (2009-09-08),
2. 7342016 - Farnesyl protein transferase inhibitors as antitumor agents (2008-03-11),
3. 6800636 - Farnesyl protein transferase inhibitors (2004-10-05),
4. 6740661 - Farnesyl protein transferase inhibitors (2004-05-25),
5. 6399615 - Farnesyl protein transferase inhibitors (2002-06-04),
6. 6372747 - Farnesyl protein transferase inhibitors (2002-04-16),
7. 6362188 - Farnesyl protein transferase inhibitors (2002-03-26),
8. 6214827 - Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases (2001-04-10),
9. 6159984 - Farnesyl protein transferase inhibitors (2000-12-12),
10. 5958940 - Tricyclic compounds useful as inhibitors of farnesyl-protein transferase (1999-09-28),
11. 5958890 - Tricyclic compounds useful for inhibition of G-protein function and for (1999-09-28),
12. 5939416 - Benzo (5,6) cycloheptapyridine compounds useful as farnesyl protein (1999-08-17),
13. 5891872 - Tricyclic compounds (1999-04-06),
14. 5801175 - Tricyclic compounds useful for inhibition of G-protein function and for (1998-09-01),
15. 5739104 - Anti-fungal agents (1998-04-14),

Title: **Innovative Contributions of Dinanath F. Rane in Cancer Research**

Introduction

Dinanath F. Rane, based in Morganville, NJ, has made significant contributions to the field of cancer research, as evidenced by his impressive portfolio of 26 patents. His innovative approach to drug development has paved the way for new treatments that target specific protein transfer processes involved in cancer progression.

Latest Patents

Rane's latest patents highlight his focus on farnesyl protein transferase inhibitors. One of his notable inventions discloses compounds designed to treat cancer, detailing a formula where R represents various functional groups bound to an imidazolylalkyl group. This groundbreaking work includes methods for both treating cancer and inhibiting farnesyl protein transferase through these novel compounds. Another patent features innovative tricyclic compounds that serve as effective antitumor agents. These compounds can also be formulated into pharmaceutical compositions, providing new avenues for cancer therapy.

Career Highlights

Throughout his career, Dinanath F. Rane has held pivotal roles in prominent pharmaceutical companies such as Schering Corporation and Pharmacopeia Inc. His work has not only garnered numerous patents but has also contributed significantly to advancing pharmaceutical science, particularly in the treatment of cancer.

Collaborations

Rane has collaborated with esteemed colleagues in the field, including Ronald J. Doll and Alan K. Mallams. These partnerships have further enriched his research and have been instrumental in his contributions to innovative cancer therapies.

Conclusion

Dinanath F. Rane’s extensive work and patents in cancer treatment exemplify the role of inventors in advancing medical science. His innovative compounds and collaboration with industry peers mark him as a significant contributor to the field, with the potential to improve patient outcomes through targeted therapies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…